DOACs Are Contraindicated in AF with Moderate-to-Severe Mitral Stenosis—Warfarin Is Mandatory
Direct oral anticoagulants (DOACs) cannot be used in patients with atrial fibrillation and moderate-to-severe mitral stenosis; warfarin with a target INR of 2.0–3.0 is the only acceptable anticoagulant for this population. 1
Guideline-Based Contraindication
Both the 2024 ESC and 2019 AHA/ACC/HRS guidelines explicitly state that DOACs are recommended for stroke prevention in AF except in patients with moderate-to-severe mitral stenosis or mechanical heart valves. 1
Class I recommendation (ESC): Direct oral anticoagulants are recommended in preference to VKAs to prevent ischemic stroke and thromboembolism, except in patients with mechanical heart valves or moderate-to-severe mitral stenosis. 1
Class III: Harm (AHA/ACC/HRS): The exclusion criteria are explicitly defined as moderate-to-severe mitral stenosis or a mechanical heart valve, making DOAC use contraindicated in these populations. 1
Why DOACs Are Contraindicated
All landmark DOAC trials systematically excluded patients with moderate-to-severe mitral stenosis, meaning there is no randomized controlled trial evidence supporting their safety or efficacy in this population. 2, 3, 4
The RE-ALIGN trial demonstrated excess thromboembolic events and major bleeding when dabigatran was used in patients with mechanical valves, reinforcing the contraindication for valvular heart disease requiring warfarin. 5
Rheumatic mitral stenosis (the most common etiology of moderate-to-severe mitral stenosis) creates unique hemodynamic and thrombogenic conditions that were never studied in DOAC trials. 6, 7
Warfarin Is the Only Option
Warfarin with a target INR of 2.5 (acceptable range 2.0–3.0) is mandatory for all patients with moderate-to-severe mitral stenosis and AF. 1, 7, 5
Monitoring Requirements:
- Weekly INR checks during warfarin initiation until therapeutic range is achieved 1, 7
- Monthly INR monitoring once stable in therapeutic range 1, 7
- Annual reassessment of renal and hepatic function 1
- Strive for high Time in Therapeutic Range (TTR) ideally ≥65–70% 5
Evidence Against DOACs in Mitral Stenosis
While some observational studies have suggested potential benefit of DOACs in mitral stenosis, the highest-quality evidence contradicts this:
A large randomized controlled trial (n=4,531) showed that warfarin led to significantly lower rates of cardiovascular events or mortality compared to rivaroxaban in patients with moderate-to-severe mitral stenosis, without higher major bleeding rates. 3
A 2023 systematic review concluded that current evidence "discourages using NOACs for patients with moderate to severe MS and supports the current treatment guidelines" favoring warfarin. 3
Observational studies 8, 9 showing potential DOAC benefit had critical limitations: severity of mitral stenosis was often not determined, heterogeneous etiologies were included, and many patients likely had only mild stenosis. 2, 3
Common Pitfalls to Avoid
Do not use CHA₂DS₂-VASc score alone to decide on anticoagulation type—the presence of moderate-to-severe mitral stenosis automatically mandates warfarin regardless of stroke risk score. 1
Do not confuse "nonvalvular AF" with absence of valve disease—nonvalvular AF simply means AF without moderate-to-severe mitral stenosis or mechanical valves; patients can have other valve lesions and still receive DOACs. 1, 2
Do not use antiplatelet therapy (aspirin, clopidogrel) as an alternative to warfarin—antiplatelet agents reduce stroke risk by only 19–22% versus warfarin's 62–64% reduction. 6
Do not switch to a DOAC if TTR is suboptimal—instead, intensify INR monitoring and patient education while maintaining warfarin therapy. 7
Special Considerations
If left atrial thrombus is present on transesophageal echocardiography, consider a higher target INR of 3.0 (range 2.5–3.5) until thrombus resolution. 7
Bioprosthetic valves implanted for rheumatic mitral stenosis still require warfarin (not DOACs) because the underlying rheumatic pathology maintains high thromboembolic risk. 5
Patients in sinus rhythm with moderate-to-severe mitral stenosis and additional risk factors (left atrial diameter ≥55 mm, prior embolism, or left atrial thrombus) should also receive warfarin. 7